Assessment of Cyclosporine Pharmacokinetic Parameters to Facilitate Conversion From C0 to C2 Monitoring in Heart Transplant Recipients

Transplantation Proceedings

Volumn 39, Issue 10, 2007, Pages 3334-3339

  Davies, R A ^a   Veinot, J P ^a   Williams, K ^a   Haddad, H ^a   Baker, A ^a   Donaldson, J ^a   Pugliese, C ^a   Struthers, C ^a   Masters, R G ^a   Hendry, P J ^a   Mesana, T ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; DILTIAZEM; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BIOPSY; CREATININE; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 37049019460     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.08.109     Document Type: Article

References (22)

1. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931
2. Goldstein D.J., Zuech N., Sehgal V., et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 63 (1997) 664
3. Lindholme A., and Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54 (1993) 205
4. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68 (1999) 55
5. Levy G. C2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. BioDrugs 15 (2001) 279
6. Johnston A., David O.J., and Cooney G.F. Pharmacokinetic validation of neoral absorption profiling. Transplant Proc 32 3A Suppl (2000) 53S
7. 2 monitoring: a review. Transplantation 73 Suppl (2002) S3
8. Levy G., Thervet E., Lake J., et al. Patient management by Neoral C2 monitoring: an international consensus. Transplantation 73 Suppl (2002) S12
9. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 72 (2001) 1024
10. Cole E., Maham N., Cardella C., et al. Clinical benefits of Neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 75 (2003) 2086
11. Einecke G., Mai I., Fritsche L., et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 19 (2004) 215
12. Cantarovich M., Barkun J.S., Tchervenkov J.I., et al. Comparison of Neoral dose monitoring with cyclosporine through levels versus 2-hr post-dose levels in stable liver transplant patients. Transplantation 66 (1998) 1621
13. Cantarovich M., Besner J.G., Barkun J.S., et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12 (1998) 243
14. Cantarovich M., Elstein E., de Varennes B., et al. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 68 (1999) 1839
15. Billingham M.E., Cary N.R., Hammond M.E., Kemnitz J., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9 (1990) 587
16. McAllister Jr. H.A. Histologic grading of cardiac allograft rejection: a quantitative approach. J Heart Transplant 9 (1990) 277
17. Delgado D.H., Rao V., Hamel J., et al. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: Improvement in clinical outcomes. J Heart Lung Transplant 24 (2005) 1343
18. Mathias H.C., Ozalp F., Will M.B., et al. A randomized, controlled trial of C0- vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant 24 (2005) 2137
19. Solari S.G., Goldberg L.R., DeNofrio D., et al. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. Ther Drug Monit 27 (2005) 417
20. Caforio A.L., Tona F., Piaserico S., et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 18 (2005) 116
21. Fiocchi R., Iamele L., Torre L., et al. C(2) blood levels in heart-transplanted patients immunosuppressed on a trough level-based regimen. Transplant Proc 33 (2001) 3115
22. Ray J.E., Keogh A.M., McLachlan A.J., et al. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 22 (2003) 715